文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

局部晚期宫颈癌晚期胃肠道不良反应的严重程度与持续性:EMBRACE-I 研究启示

Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-10-20

基于 EMBRACE-I 研究 1416 例局部晚期宫颈癌患者,前瞻性评估医生报告(CTCAE)和患者报告(EORTC)的胃肠道症状。结果显示直肠 D2cm3、ICRU 直肠阴道参考点及肠道 D2cm3 是胃肠道不良反应的风险因素,外照射处方剂量 45 Gy 较 50 Gy 风险更低,V57Gy 较大时风险增加。

要点

  • 直肠 D2cm3、ICRU RV-RP 和肠道 D2cm3 是晚期胃肠道不良反应的关键剂量学风险因素。
  • 外照射处方剂量 45 Gy 的胃肠道症状风险低于 50 Gy,V57Gy 较大时风险增加。
  • 医生报告 G≥3 事件中肛门/直肠、乙状结肠、结肠/小肠发生率分别为 2.8%、1.8%、2.3%。

核心结论

  • 外照射和图像引导自适应近距离放疗均对局部晚期宫颈癌治疗后的胃肠道症状有贡献。
  • 直肠 D2cm3、ICRU RV-RP 和肠道 D2cm3 是胃肠道不良反应的风险因素。

研究设计与样本

  • EMBRACE-I 研究纳入 1416 例局部晚期宫颈癌患者,其中 1199 例采用 CTCAE 医生评估、1002 例采用 EORTC 患者报告进行前瞻性评估。
  • 采用 Cox 回归分析个体症状,Logistic 回归分析持续性症状(至少半数随访时存在)。

主要发现

  • 医生报告 G≥3 肛门/直肠、乙状结肠、结肠/小肠事件发生率分别为 2.8%、1.8%、2.3%。
  • G≥2 症状中腹泻和腹胀最常见,发生率分别为 8.5% 和 9.9%。
  • 直肠 D2cm3 和 ICRU RV-RP 与 G≥3 肛门/直肠事件及中度/持续性腹泻、直肠炎、出血、腹部绞痛、排便控制困难相关。
  • 肠道 D2cm3 与 G≥3 乙状结肠和结肠/小肠事件及中度/持续性腹泻、腹胀相关。
  • 外照射处方剂量与 G≥3 肛门/直肠事件、腹泻、排便控制困难相关;大淋巴结boost(V57Gy)患者 G≥3 乙状结肠事件、中度/持续性腹泻、直肠炎、绞痛风险更高。

关键数值与推荐

  • 医生报告 G≥3 肛门/直肠、乙状结肠、结肠/小肠事件发生率分别为 2.8%、1.8%、2.3%。
  • G≥2 腹泻和腹胀发生率分别为 8.5% 和 9.9%。
  • 外照射处方剂量 45 Gy 的胃肠道症状风险低于 50 Gy,V57Gy 较大时风险增加。

临床怎么用

  • 放疗计划时应关注直肠 D2cm3、ICRU RV-RP 和肠道 D2cm3 等剂量学参数以降低晚期胃肠道毒性。
  • 外照射处方剂量选择 45 Gy 可能较 50 Gy 降低胃肠道症状风险,大淋巴结boost(V57Gy)时需警惕乙状结肠等毒性。
  • 结合医生评估和患者报告的症状进行前瞻性随访,关注持续性胃肠道症状。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The purpose was to evaluate patient- and treatment-related risk factors for physician-assessed and patient-reported gastrointestinal (GI) symptoms after radio(chemo)therapy and image guided adaptive brachytherapy in locally advanced cervical cancer. METHODS AND MATERIALS: Of 1416 patients from the EMBRACE-I study, 1199 and 1002 were prospectively evaluated using physician-assessed (Common Terminology Criteria for Adverse Events [CTCAE]) and patient-reported (European Organization for Research and Treatment of Cancer [EORTC]) GI symptoms, respectively. CTCAE severe grade (grade [G] ≥3) events were pooled according to the location in the GI tract (anus/rectum, sigmoid, and colon/small bowel). CTCAE G ≥2 and EORTC "very much" and "quite a bit" plus "very much" scores (≥ "quite a bit") were analyzed for individual symptoms with Cox regression. Logistic regression was used for persistent G ≥1 and EORTC ≥ "quite a bit" symptoms, defined if present in at least half of follow-ups. RESULTS: The incidence of G ≥3 events was 2.8%, 1.8%, and 2.3% for G ≥3 anus/rectum, sigmoid, and colon/small bowel events, respectively. Among G ≥2 symptoms, diarrhea and flatulence were the most prevalent (8.5% and 9.9%, respectively). Among patient-related factors, baseline morbidity, increasing age, smoking status, and low body mass index were associated with GI symptoms to varying degrees. Among treatment-related factors, rectum D2cm3 and the International Commission on Radiation Units and Measurements recto-vaginal reference point (ICRU RV-RP) correlated with G ≥3 anus/rectum events and moderate/persistent diarrhea, proctitis, bleeding, abdominal cramps, and difficulty in bowel control. Bowel D2cm3 correlated with G ≥3 sigmoid and colon/small bowel events and moderate/persistent diarrhea and flatulence. For external beam radiation therapy (EBRT), prescription dose correlated with G ≥3 anus/rectum, diarrhea, and difficulty in bowel control. Patients with large lymph-node boost (V57Gy) were at higher risk for G ≥3 sigmoid events, moderate/persistent diarrhea, proctitis, and cramps. CONCLUSIONS: The analysis showed that both EBRT and image guided adaptive brachytherapy contribute to GI symptoms after locally advanced cervical cancer treatment. Rectum D2cm3, ICRU RV-RP , and bowel D2cm3 are risk factors for GI morbidity. The risk for various symptoms was lower with an EBRT prescription of 45 Gy than 50 Gy and increased with larger V57Gy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Spampinato S, Jensen NBK, Pötter R, et al. Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. Int J Radiat Oncol Biol Phys. 2021. PMID: 34678431. doi:10.1016/j.ijrobp.2021.09.055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。